Phase Ia Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Recombinant Humanized Anti-CD20 Monoclonal Antibody for Injection(B001)
Phase of Trial: Phase I
Latest Information Update: 29 Mar 2018
At a glance
- Drugs B 001 (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
- Sponsors Shanghai Pharmaceuticals Holding
- 31 Aug 2018 Biomarkers information updated
- 26 Mar 2018 Planned End Date changed from 15 Oct 2019 to 18 Feb 2020.
- 26 Mar 2018 Planned primary completion date changed from 25 Jul 2019 to 7 Jan 2020.